A Phase II Clinical Trial to Investigate ARID1A Mutation and CXCL13 Expression in the Pre-Treatment Tumor Samples as a Combinatorial Predictive Biomarker for Immune Checkpoint Therapy in Metastatic Urothelial Cancer
Latest Information Update: 13 Feb 2024
At a glance
- Drugs Nivolumab (Primary)
- Indications Bladder cancer; Carcinoma; Renal cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Therapeutic Use
- 03 Nov 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 03 Nov 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
- 08 May 2023 Status changed from not yet recruiting to recruiting.